William Blair Issues Pessimistic Outlook for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities researchers at William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings per share of ($1.39) for the quarter, down from their previous forecast of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Other analysts have also issued reports about the company. HC Wainwright cut their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a report on Friday, March 7th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Wells Fargo & Company cut their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, Canaccord Genuity Group cut their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a report on Monday, March 10th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Stock Up 1.3 %

Shares of Arcturus Therapeutics stock opened at $14.08 on Monday. The stock has a market cap of $381.85 million, a PE ratio of -6.34 and a beta of 2.96. The business has a fifty day simple moving average of $16.64 and a 200-day simple moving average of $18.29. Arcturus Therapeutics has a 12 month low of $12.75 and a 12 month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The business had revenue of $22.77 million during the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently bought and sold shares of ARCT. Virtus ETF Advisers LLC raised its holdings in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 1,132 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth about $71,000. National Bank of Canada FI increased its stake in shares of Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 4,784 shares during the period. Kennedy Capital Management LLC increased its stake in shares of Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 2,036 shares during the period. Finally, Sherbrooke Park Advisers LLC bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth about $200,000. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.